FILANA THERAPEUTICS, INC. - 10-Q Filing
Filana Therapeutics reported a net loss of $10.3 million for the first quarter ended March 31, 2026, compared to a net loss of $23.4 million in the same period last year. The company's operating expenses were $11.2 million (vs. $24.6 million YoY), driven by research and development ($4.5 million vs. $13.7 million) and general/administrative costs ($6.6 million vs. $10.9 million). Cash and cash equivalents decreased to $86.6 million from $95.5 million at the end of 2025.
Tickers: $SAVA